INS and type 2 diabetes mellitus: These effects on hepatic insulin sensitivity are supported by GLP-1 studies in patients with [20], [28] and without [19], [21] type 2 diabetes, albeit that the duration of treatment in these studies was shorter and the underlying status of liver disease was unknown.